References in periodicals archive ?
We moved to a comparison study as a potential treatment for chemotherapy-induced peripheral neuropathy. We received a grant from the National Institute on Drug Abuse to continue research into CIPN and the potential for a new standard of care, as well as potentially replace opiates as a treatment for CIPN.
"Chemotherapy-induced peripheral neuropathy (CIPN) can interfere with daily function and quality of life, and there are no known preventive approaches," observed Gary R.
Van De Poll-Franse, "Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review," Supportive Care in Cancer, vol.
Cascella, "Chemotherapy-induced peripheral neuropathy: limitations in current prophylactic strategies and directions for future research," Current Medical Research and Opinion, vol.
Loprinzi, "Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies," European Journal of Cancer, vol.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect and occurs more frequently in patients older than 60 (Saxon, 2010).
26 May 2010 - Stockholm-listed pharma company Epicept Corp (NASDAQ: EPCTD) (STO: EPCT) said today it has enrolled over 400 patients in a phase IIb trial with drug candidate NP-1 for the treatment of chemotherapy-induced peripheral neuropathy (CPN).
The chemotherapy-induced peripheral neuropathy systematic review included evidence for pharmacological and non-pharmacological strategies; the non-pharmacological evidence is considered here (Visovsky et al, 2007).
A single oral dose of NYX-2925 produces significant analgesia up to 24 hours post-dose compared to three daily administrations and only one-hour post-dose efficacy of gabapentin in a model of chemotherapy-induced peripheral neuropathy.
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of some anticancer drugs, such as bortezomib, cisplatin, oxaliplatin, paclitaxel, thalidomide, and vincristine.
Gary Zirpoli, PhD, and colleagues analyzed data collected from 1,125 breast cancer patients enrolled in a National Cancer Institute group trial to determine whether use of dietary supplements was related to the presence of chemotherapy-induced peripheral neuropathy.
Full browser ?